Disruptive Thinking: What's Next for Pain

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
Initiatives to reduce opioid prescription and opiod use are in force, but the need for effective pain relief, especially in areas like cancer, trauma and severe chronic pain, remains a pressing one.

How can the biopharma industry develop and support the development of new analgesic drugs and other alternative treatments to pain? This panel will include perspectives on critical clinical needs and perspectives on new avenues to novel non-addictive therapies as well as the capital, public policy and regulation needed to advance non-opioid pain options to market.

(Full slide deck available below speaker list).
Moderator
photo
Managing Director, Biopharmaceuticals Equity Research
Ladenburg Thalmann & Co. Inc.
Speakers
photo
Director, Helping to End Addiction Long-term (HEAL) Initiative
National Institutes of Health
photo
Principal Deputy Administrator for Policy & Operations
Centers for Medicaid & Medicare Services
photo
President & Chief Executive Officer
Artelo Biosciences
photo
Managing Director, Biopharmaceuticals Equity Research
Ladenburg Thalmann & Co. Inc.